Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of PT010 With and Without Spacer and Charcoal
NCT03311373Phase 1Completed
- Sponsor
- Pearl Therapeutics
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of EPI-EE, glycopyrronium and formoterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Pearl Therapeutics. Primary endpoints: Maximum Plasma Concentration at 24 hours and Area Under the Plasma Concentration-time Curve From 0 to Last Measurable Concentration at 24 hours. Started Oct 2017; status: completed.
02
Drugs
EPI-EEglycopyrroniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03311373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03311373.